Touyun Biotech Group (HKSE:01332) EBIT: HK$68.76 Mil (TTM As of Dec. 2025)


HKSE:01332 Touyun Biotech Group Ltd HKSE:01332
25 GF Score
Price HK$0.16
GF Value HK$0.16
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Touyun Biotech Group EBIT?

Touyun Biotech Group HKSE:01332 +16.18% 25 EBIT is HK$68.76 Mil as of Dec. 2025. GuruFocus rates HKSE:01332 with a GF Score™ of 25/100 and a GF Value™ of HK$0.16 (Fairly Valued). The stock has 6 warning signs investors should review.

Touyun Biotech Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$28.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$68.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Touyun Biotech Group's annualized ROC % for the quarter that ended in Dec. 2025 was -20.05%. Touyun Biotech Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 22.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Touyun Biotech Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.39%.


Touyun Biotech Group  (HKSE:01332) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Touyun Biotech Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-192.05 * ( 1 - 0% )/( (955.199 + 960.386)/ 2 )
=-192.05/957.7925
=-20.05 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Touyun Biotech Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=56.394/( ( (267.836 + max(-160.221, 0)) + (242.192 + max(-121.432, 0)) )/ 2 )
=56.394/( ( 267.836 + 242.192 )/ 2 )
=56.394/255.014
=22.11 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.27 + 17.232 + 28.945) - (150.69 + 0 + 67.978)
=-160.221

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.461 + 18.241 + 29.044) - (152.422 + 0 + 25.756)
=-121.432

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Touyun Biotech Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=68.756/930.334
=7.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Touyun Biotech Group EBIT Related Terms


Touyun Biotech Group EBIT Historical Data

* Premium members only.

The historical data trend for Touyun Biotech Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Touyun Biotech Group EBIT Chart

Touyun Biotech Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -105.83 -177.53 -265.15 -69.47 68.76

Touyun Biotech Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -184.23 -32.39 -37.07 40.56 28.20

HKSE:01332 vs SW, PKG, IP: EBIT Comparison

For the Packaging & Containers subindustry, Touyun Biotech Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Touyun Biotech Group EV-to-EBIT vs Packaging & Containers Industry

For the Packaging & Containers industry and Consumer Cyclical sector, Touyun Biotech Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Touyun Biotech Group's EV-to-EBIT falls into.


HKSE:01332
25GF Score
Touyun Biotech Group Ltd HKSE:01332
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Touyun Biotech Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$68.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$68.76 Mil mean?
Touyun Biotech Group (HKSE:01332) has a EBIT of HK$68.76 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Touyun Biotech Group.
Is Touyun Biotech Group's EBIT too high?
Touyun Biotech Group's current EBIT is HK$68.76 Mil. Overall, Touyun Biotech Group has a GF Score™ of 25/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Touyun Biotech Group's EBIT compare to SW and PKG?
Touyun Biotech Group's EBIT of HK$68.76 Mil can be compared against companies in the Packaging & Containers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Packaging & Containers company?
A good EBIT depends on the Packaging & Containers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Touyun Biotech Group. Touyun Biotech Group's current EBIT is HK$68.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touyun Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, Touyun Biotech Group (HKSE:01332) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.16 — trading 1.3% below its estimated fair value. The current EBIT is HK$68.76 Mil. Touyun Biotech Group's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Touyun Biotech Group (HKSE:01332), the current EBIT is HK$68.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Touyun Biotech Group (HKSE:01332) Overvalued in 2026?

Based on GuruFocus' analysis, Touyun Biotech Group stock appears to be undervalued. The current stock price of HK$0.16 is trading 1.3% below its estimated GF Value™ of HK$0.16. GuruFocus considers Touyun Biotech Group to be Fairly Valued.

Key valuation signals for HKSE:01332:

  • EBIT: HK$68.76 Mil
  • GF Value™: HK$0.16 vs. price of HK$0.16 (1.3% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the HKSE:01332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Touyun Biotech Group Business Description

Address 6 Tonnochy Road, 12th Floor, Kwan Chart Tower, Wanchai, Hong Kong, HKG
Touyun Biotech Group Ltd is principally engaged in the (i) the manufacture and sale of packaging products; (ii) investments and trading in securities and money lending, and (iii) production and sale of Chlamydomonas reinhardtii, micro-algae and related products. The company generates majority of its revenue from packaging products segment.
25GF Score

Get the complete analysis for HKSE:01332

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.16
Price
HK$0.16
GF Value